Verastem Oncology announced that Dan Paterson, President and Chief Operating Officer, has been promoted to President and Chief Executive Officer, CEO. Brian Stuglik will retire from the CEO role and remain a member of the Board of Directors. These changes will be effective August 1, allowing for a smooth leadership transition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VSTM:
- Verastem finalizes design for confirmatory trial of Avutometinib and Defactinib
- Verastem price target lowered to $34 from $36 at RBC Capital
- Verastem price target raised to $34 from $3 at Cantor Fitzgerald
- Verastem 7.18M share Spot Secondary priced at $9.75
- Verastem announces common stock offering, no amount given